KITE-585
- Generic Name
- KITE-585
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
KITE-585 is an autologous, fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. It is being investigated in the treatment of multiple myeloma.
- Associated Conditions
- -
- Associated Therapies
- -
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 700
- Registration Number
- NCT05041309
- Locations
- 🇯🇵
Kyoto University Hospital, Kyoto, Japan
🇯🇵Okayama University Hospital, Okayama, Japan
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath